UK’s GSK to Buy US-Based Cancer Drugmaker Nuvalent for $10.6 Billion
June 9 (Reuters) – British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio. The all-cash deal values Nuvalent at approximately $124 per share, a 40% premium to its last closing price. (Reporting by DhanushVignesh Babu and Yadarisa Shabong in Bengaluru; Editing by Mrigank …